Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
- 8-K Current report
- 3.1 Exhibit 3.1
- 3.2 Exhibit 3.2
- 10.1 Exhibit 10.1
- 10.2 Exhibit 10.2
- 10.3 Exhibit 10.3
- 10.4 Exhibit 10.4
- 10.5 Exhibit 10.5
- 10.6 Exhibit 10.6
- 10.11 Exhibi 10.11
- 10.12 Exhibit 10.12
- 10.13 Exhibit 10.13
- 10.20 Exhibit 10.20
- 10.21 Exhibit 10.21
- 10.22 Exhibit 10.22
- 10.23 Exhibit 10.23
- 10.24 Exhibit 10.24
- 10.25 Exhibit 10.25
- 10.26 Exhibit 10.26
- 10.27 Exhibit 10.27
- 10.28 Exhibit 10.28
- 10.28 Exhibit 10.28(A)
- 14.1 Exhibit 14.1
- 16.1 Exhibit 16.1
- 23.1 Exhibit 23.1
- 99.1 Exhibit 99.1
- 99.2 Exhibit 99.2
- 99.3 Exhibit 99.3
- 99.4 Exhibit 99.4
- 99.5 Exhibit 99.5
- 99.6 EXHIBIT99.6
- Download Excel data file
- View Excel data file
AEON similar filings
- 19 Oct 23 AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
- 2 Oct 23 Changes in Registrant's Certifying Accountant
- 11 Aug 23 Financial Statements and Exhibits
- 27 Jul 23 Index to Financial Statements
- 24 Jul 23 Corporate Presentation July 2023
- 17 Jul 23 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
- 11 Jul 23 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
Filing view
External links
Exhibit 23.1
Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm
We consent to the inclusion of our report dated March 9, 2023, relating to the consolidated financial statements of AEON Biopharma, Inc. (Old AEON) as of and for the years ended December 31, 2022 and 2021 appearing in this Current Report on Form 8-K of AEON Biopharma, Inc. (formerly Priveterra Acquisition Corp.).
/s/ Ernst & Young LLP |
Irvine, CA
July 27, 2023